Acetyl-CoA carboxylase (ACC) as a therapeutic target for metabolic syndrome and recent developments in ACC1/2 inhibitors - PubMed (original) (raw)
Review
. 2019 Oct;28(10):917-930.
doi: 10.1080/13543784.2019.1657825. Epub 2019 Aug 29.
Affiliations
- PMID: 31430206
- DOI: 10.1080/13543784.2019.1657825
Review
Acetyl-CoA carboxylase (ACC) as a therapeutic target for metabolic syndrome and recent developments in ACC1/2 inhibitors
Leyuan Chen et al. Expert Opin Investig Drugs. 2019 Oct.
Abstract
Introduction: Acetyl-CoA Carboxylase (ACC) is an essential rate-limiting enzyme in fatty acid metabolism. For many years, ACC inhibitors have gained great attention for developing therapeutics for various human diseases including microbial infections, metabolic syndrome, obesity, diabetes, and cancer. Areas covered: We present a comprehensive review and update of ACC inhibitors. We look at the current advance of ACC inhibitors in clinical studies and the implications in drug discovery. We searched ScienceDirect ( https://www.sciencedirect.com/ ), ACS ( https://pubs.acs.org/ ), Wiley ( https://onlinelibrary.wiley.com/ ), NCBI ( https://www.ncbi.nlm.nih.gov/ ) and World Health Organization ( https://www.who.int/ ). The keywords used were Acetyl-CoA Carboxylase, lipid, inhibitors and metabolic syndrome. All documents were published before June 2019. Expert opinion: The key regulatory role of ACC in fatty acid synthesis and oxidation pathways makes it an attractive target for various metabolic diseases. In particular, the combination of ACC inhibitors with other drugs is a new strategy for the treatment of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Expanding the clinical indications for ACC inhibitors will be one of the hot directions in the future. It is also worth looking forward to exploring safe and efficient inhibitors that act on the BC domain of ACC.
Keywords: Acetyl-CoA carboxylase; inhibitors; lipid; metabolic syndrome.
Similar articles
- Recent development in acetyl-CoA carboxylase inhibitors and their potential as novel drugs.
Wu X, Huang T. Wu X, et al. Future Med Chem. 2020 Mar;12(6):533-561. doi: 10.4155/fmc-2019-0312. Epub 2020 Feb 12. Future Med Chem. 2020. PMID: 32048880 Review. - Treating the metabolic syndrome: acetyl-CoA carboxylase inhibition.
Harwood HJ Jr. Harwood HJ Jr. Expert Opin Ther Targets. 2005 Apr;9(2):267-81. doi: 10.1517/14728222.9.2.267. Expert Opin Ther Targets. 2005. PMID: 15934915 Review. - Inhibitors of mammalian acetyl-CoA carboxylase.
Corbett JW, Harwood JH Jr. Corbett JW, et al. Recent Pat Cardiovasc Drug Discov. 2007 Nov;2(3):162-80. doi: 10.2174/157489007782418928. Recent Pat Cardiovasc Drug Discov. 2007. PMID: 18221116 Review. - Targeting acetyl-CoA carboxylases: small molecular inhibitors and their therapeutic potential.
Luo DX, Tong DJ, Rajput S, Wang C, Liao DF, Cao D, Maser E. Luo DX, et al. Recent Pat Anticancer Drug Discov. 2012 May 1;7(2):168-84. doi: 10.2174/157489212799972918. Recent Pat Anticancer Drug Discov. 2012. PMID: 22339356 Review. - GS-0976 (Firsocostat): an investigational liver-directed acetyl-CoA carboxylase (ACC) inhibitor for the treatment of non-alcoholic steatohepatitis (NASH).
Alkhouri N, Lawitz E, Noureddin M, DeFronzo R, Shulman GI. Alkhouri N, et al. Expert Opin Investig Drugs. 2020 Feb;29(2):135-141. doi: 10.1080/13543784.2020.1668374. Epub 2019 Sep 19. Expert Opin Investig Drugs. 2020. PMID: 31519114 Free PMC article. Review.
Cited by
- Emerging mechanisms and promising approaches in pancreatic cancer metabolism.
Wu H, Fu M, Wu M, Cao Z, Zhang Q, Liu Z. Wu H, et al. Cell Death Dis. 2024 Aug 1;15(8):553. doi: 10.1038/s41419-024-06930-0. Cell Death Dis. 2024. PMID: 39090116 Free PMC article. Review. - Identification of potential key lipid metabolism-related genes involved in tubular injury in diabetic kidney disease by bioinformatics analysis.
Fan Y, He J, Shi L, Zhang M, Chen Y, Xu L, Han N, Jiang Y. Fan Y, et al. Acta Diabetol. 2024 Aug;61(8):1053-1068. doi: 10.1007/s00592-024-02278-1. Epub 2024 May 1. Acta Diabetol. 2024. PMID: 38691241 - Oroxin A from Oroxylum indicum improves disordered lipid metabolism by inhibiting SREBPs in oleic acid-induced HepG2 cells and high-fat diet-fed non-insulin-resistant rats.
Cai T, Xu X, Dong L, Liang S, Xin M, Wang T, Li T, Wang X, Zheng W, Wang C, Xu Z, Wang M, Song X, Li L, Li J, Sun W. Cai T, et al. Heliyon. 2024 Apr 3;10(7):e29168. doi: 10.1016/j.heliyon.2024.e29168. eCollection 2024 Apr 15. Heliyon. 2024. PMID: 38617966 Free PMC article. - Chloroflexus aurantiacus acetyl-CoA carboxylase evolves fused biotin carboxylase and biotin carboxyl carrier protein to complete carboxylation activity.
Shen J, Wu W, Wang K, Wu J, Liu B, Li C, Gong Z, Hong X, Fang H, Zhang X, Xu X. Shen J, et al. mBio. 2024 May 8;15(5):e0341423. doi: 10.1128/mbio.03414-23. Epub 2024 Apr 4. mBio. 2024. PMID: 38572988 Free PMC article. - CMS121: a novel approach to mitigate aging-related obesity and metabolic dysfunction.
Dafre AL, Zahid S, Probst JJ, Currais A, Yu J, Schubert D, Maher P. Dafre AL, et al. Aging (Albany NY). 2024 Mar 20;16(6):4980-4999. doi: 10.18632/aging.205673. Epub 2024 Mar 20. Aging (Albany NY). 2024. PMID: 38517358 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous